Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 708 participants.

Also called NCT01778049

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 708 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01778049
  • EudraCT 2012-002271-34
Other papers using this trial's data
  • Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials Diabetes, obesity & metabolism, 2017-02 DOI, PubMed 27762093

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Canada, El Salvador, Germany, Italy, Portugal, Russia, Spain, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01778049. Randomized; double masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2015-03 (actual). Results posted on 2016-04-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
BI 10773
Intervention (Drug)
BI 10773 Placebo
Intervention (Drug)
BI 10773 / BI 1356
Intervention (Drug)
BI 10773
Intervention (Drug)
BI 10773 / BI 1356
Intervention (Drug)
BI 10773 / BI 1356 Placebo
Intervention (Drug)
BI 10773
Intervention (Drug)
BI 10773
Intervention (Drug)
BI 10773
Intervention (Drug)
BI 10773 / BI 1356 Placebo
Intervention (Drug)
BI 10773 Placebo
Intervention (Drug)
BI 10773 / BI 1356 Placebo
Intervention (Drug)
BI 10773
Intervention (Drug)
BI 10773 / BI 1356 Placebo
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01778049
Content hash
8c2604fca733485ec4a5a82c029cf13e810e5d1de2741c8a79efcb48bcd76440